Summary
The aim of this study was to determine the optimal dosage regimen of cisapride for the treatment of idiopathic gastroparesis.
We studied 17 patients with documented idiopathic gastroparesis in a three-way, cross-over, double-blind study with three 4-day treatment periods separated by at least 3 days without treatment. In each period, the patients were preloaded with cisapride (10 mg tid) for three days. On the fourth day (the test day) they took either 10 mg or 20 mg before breakfast and placebo before lunch (1×10 mg), (1×20 mg), or 10 mg before breakfast and 10 mg before lunch (2×10 mg). The medications were taken 30 min before meals. Gastric emptying of solids (99mTc-sulphur colloid) was measured at lunch time under basal conditions and during each treatment period. Plasma concentrations of cisapride were determined before the breakfast dose, before the lunch dose, and at 1, 2, 3, 4 and 5 h after.
The greatest acceleration in gastric emptying occurred with the 2×10 mg regimen. Although the single morning dose of 20 mg also significantly accelerated gastric emptying (P=0.05), the reduction was not as substantial.
Plasma concentrations of cisapride were significantly higher after 2×10 mg than after 1×20 mg or 1×10 mg. There was a significant relation between cisapride plasma concentrations and changes in gastric emptying. Peak concentrations of cisapride greater than 60 ng·ml−1 were invariably associated with acceleration of gastric emptying.
We conclude that cisapride 10 mg tid before meals is the optimal dose for the treatment of idiopathic gastroparesis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Reyntjens A, Verlinden M, Schuurkes J, Van Nueten J, Janssen PAJ (1984) New approach to gastrointestinal motor dysfunction: non antidopaminergic, non-cholinergic stimulation with cisapride. Curr Ther Res 36: 1029–1037
Stacher G, Bergmann H, Wiesnagrotzki S, et al. (1987) Intravenous cisapride accelerates delayed gastric emptying and increases antral contraction amplitude in patients with primary anorexia nervosa. Gastroenterology 92: 1000–1006
Rezende-Filho J, Di Lorenzo C, Dooley CP, Valenzuela JE (1989) Cisapride stimulates antral motility and decreases biliary reflux in patients with severe dyspepsia. Dig Dis Sci 34: 1057–1062
Testoni PA, Bagnolo F, Fanti L, Passaretti S, Tittobello A (1990) Longterm oral cisapride improves interdigestive antroduodenal motility in dyspeptic patients. Gut 31: 286–290
Johnson AG (1989) The effects of cisapride on antroduodenal co-ordination and gastric emptying. Scand J Gastroenterol 24 [Suppl 165]: 36–43
Jian R, Ducrot F, Piedeloup C, Mary JY, Najean Y, Bernier JJ (1985) Measurement of gastric emptying in dyspeptic patients: effect of a new gastrokinetic agent (cisapride). Gut 26: 352–358
Corinaldesi R, Stanghellini V, Raiti C, Rea E, Salgemini R, Barbara L (1987) Effect of chronic administration of cisapride on gastric emptying of a solid meal and on dyspeptic symptoms in patients with idiopathic gatroparesis. Gut 28: 300–305
Horowitz M, Maddox A, Harding PE, et al. (1987) Effect of cisapride on gastric and oesophageal emptying in insulin-dependent diabetes mellitus. Gastroenterology 93: 1899–1907
Urbain JC, Siegel JA, Debie NC, Pauwels SP (1988) Effect of cisapride on gastric emptying in dyspeptic patients. Dig Dis Sci 33: 779–783
Jian R, Ducrot F, Ruskone A et al. (1989) Symptomatic, radionuclide and therapeutic assessment of chronic idiopathic dyspepsia. Dig Dis Sci 34: 657–664
Harrington RA, Hamilton CW, Brogden RN, Linkewich JA, Romankiewicz JA, Heel RC (1983) Metoclopramide. An updated review of its pharmacological properties and clinical use. Drugs 25: 451–494
Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS (1982) Domperidone: A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs 24: 360–400
Barone JA, Huang Y, Bierman RH et al. (1987) Bioavailability of three oral dosage forms of cisapride, a gastrointestinal stimulant agent. Clin Pharmacol 6: 640–645
Van Peer A, Woestenborhs R, Verlinden M, Meuldermans W, Heykants J (1986) Pharmacokinetics of cisapride in healthy volunteers. Digestion 34: 138
Corinaldesi R, Paternicò A, Stanghellini V et al. (1991) Patients with duodenitis have gastric secretory and motor functions like those of duodenal ulcer patients: results of a short-term treatment with ranitidine. J Clin Gastroenterol 13: 296–302
Tothill P, McLoughlin GP, Heading RC (1978) Technique and errors in scintigraphic measurement of gastric emptying. J Nucl Med 19: 256–261
Elashoff JD, Reedy JT, Meyer JH (1982) Analysis of gastric emptying data. Gastroenterology 83: 1306–1312
Ayd FJ Jr (1973) Rational Pharmacotherapy: once-a-day drug dosage. Dis Nerv Syst 34: 371–378
Van Peer A, Verlinden M, Woestenborghs R, Meuldermans W, Heykants J, Reyntjens A (1988) Clinical pharmacokinetics of cisapride. In: Johnson AG, Lux G (eds) Progress in the treatment of gastrointestinal motility disorders: the role of cisapride. Excerpta Medica, Amsterdam Hong Kong Manila, pp 23–29
Rowbotham DJ, Nimmo WS (1987) Effect of cisapride on morphine-induced delay in gastric emptying. Br J Anaesth 59: 536–539
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Corinaldesi, R., Stanghellini, V., Tosetti, C. et al. The effect of different dosage schedules of cisapride on gastric emptying in idiopathic gastroparesis. Eur J Clin Pharmacol 44, 429–432 (1993). https://doi.org/10.1007/BF00315538
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315538